Article
Medicine, General & Internal
Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne N. Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue-Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs
Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Gerardo Rosati, Sara Lonardi, Fabio Galli, Maria Di Bartolomeo, Monica Ronzoni, Maria G. Zampino, Maria Banzi, Alberto Zaniboni, Felice Pasini, Silvia Bozzarelli, Silvio K. Garattini, Daris Ferrari, Vincenzo Montesarchio, Andrea Mambrini, Libero Ciuffreda, Francesca Galli, Valeria Pusceddu, Chiara Carlomagno, Paolo Bidoli, Domenico Amoroso, Anna M. Bochicchio, Luca Frassineti, Domenico Corsi, Domenico Bilancia, Alessandro Pastorino, Alfonso De Stefano, Roberto Labianca
Summary: Older patients receiving oxaliplatin-based adjuvant therapy have worse prognostic factors and reduced treatment compliance, leading to decreased efficacy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Meridith C. Ginesi, Jonathan T. Bliggenstorfer, Daphine M. Kwesiga, Samantha H. Xu, Diana Jodeh, J. Eva Selfridge, Sharon L. Stein, Emily F. Steinhagen
Summary: This study investigated the use of chemotherapy and its impact on survival in stage II colon cancer patients. It found that factors associated with not receiving chemotherapy in high-risk patients included increasing age, distance from the treatment facility, Charlson-Deyo score, and lack of insurance. Chemotherapy was associated with improved overall survival, but only high-risk patients benefited from it.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Nancy N. Baxter, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M. Morris, Erika Ruiz-Garcia, Y. Nancy You, Jeffrey A. Meyerhardt
Summary: The study aims to develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Xin Chen, Junhao Tu, Xiaolan Xu, Wen Gu, Lei Qin, Haixin Qian, Zhenyu Jia, Chuntao Ma, Yinkai Xu
Summary: This study found that adjuvant chemotherapy in elderly patients with stage III colon cancer can reduce cancer-specific mortality rate, but the benefit of chemotherapy in stage II colon cancer patients is suboptimal.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lana Khalil, Xingyu Gao, Jeffrey M. Switchenko, Olatunji B. Alese, Mehmet Akce, Christina Wu, Maria Diab, Bassel F. El-Rayes, Walid L. Shaib
Summary: This age group-based study examines the impact of adjuvant therapy in patients older than 70 with colon cancer. The study suggests that multi-agent chemotherapy may have better survival outcomes compared to single-agent chemotherapy in this age group.
Article
Oncology
Zhonglin Hao, Saurabh Parasramka, Quan Chen, Aasems Jacob, Bin Huang, Timothy Mullett, Al B. Benson
Summary: For resectable colon cancer with synchronous liver or lung metastasis, neoadjuvant chemotherapy before surgical resection of all lesions, especially in non-academic settings, has shown an overall survival advantage over adjuvant chemotherapy after surgery.
Article
Oncology
Qiangkang Lin, Huizhen Zhou, Si Shi, Jixu Lin, Wangxin Yan
Summary: The aim of this study was to investigate the survival benefit of adjuvant chemotherapy in patients with colon cancer with the solitary tumor deposit (TD). The study found that adjuvant chemotherapy administration significantly improved overall survival (OS) and colon cancer-specific survival (CSS) in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Takayuki Yoshino, Eiji Oki, Toshihiro Misumi, Masahito Kotaka, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Yasuhiro Sakamoto, Manabu Shiozawa, Masayasu Nishi, Tetsuya Horiuchi, Hisakazu Yamagishi, Junichi Sakamoto, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori
Summary: The study demonstrated that shortening adjuvant therapy duration from 6 to 3 months did not compromise efficacy in Asian patients with colon cancer, and also reduced the rate of long-lasting peripheral sensory neuropathy. In this setting, 3 months of CAPOX therapy is a suitable adjuvant treatment option.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Brendan L. Hagerty, John G. Aversa, Dana A. Dominguez, Jeremy L. Davis, Jonathan M. Hernandez, James T. McCormick, Andrew M. Blakely
Summary: In patients with stage II colon cancer, young patients frequently receive adjuvant chemotherapy while older patients rarely receive adjuvant therapy. Age is an independent factor associated with the receipt of adjuvant chemotherapy.
DISEASES OF THE COLON & RECTUM
(2022)
Article
Oncology
Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Soren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray, FOxTROT Collaborative Grp
Summary: Neoadjuvant chemotherapy shows potential benefits for locally advanced colon cancer compared to postoperative chemotherapy. In this study, patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly assigned to receive 6 weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy followed by either 18 or 24 weeks postoperatively. Results indicate that neoadjuvant chemotherapy results in marked downstaging of tumors and lower rates of incomplete resections and disease recurrence within 2 years.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Julien Taieb, Valerie Taly, Julie Henriques, Camille Bourreau, Laurent Mineur, Jaafar Bennouna, Jerome Desrame, Christophe Louvet, Celine Lepere, May Mabro, Joelle Egreteau, Olivier Bouche, Claire Mulot, Katia Hormigos, Kariman Chaba, Thibault Mazard, Aimery de Gramont, Dewi Vernerey, Thierry Andre, Pierre Laurent-Puig
Summary: The study showed that ctDNA presence in patients with stage III colon cancer is associated with disease prognosis, with different prognostic value observed in certain subgroups.
CLINICAL CANCER RESEARCH
(2021)
Article
Surgery
Andrea M. Mesiti, Julianna Brouwer, Mehraneh D. Jafari, Yuqing Qiu, Lari Wenzel, Joseph Carmichael, Chelsea McKinney, Jason A. Zell, Alessio Pigazzi
Summary: This study aimed to assess the willingness of the general public to accept immediate adjuvant chemotherapy after surgery for colon cancer. The results showed that respondents with higher education were more likely to accept IAC for improved survival and quality of life, males were more likely to accept early termination of chemotherapy with possible side effects, and higher income respondents were more likely to accept early termination of chemotherapy without survival impact. Furthermore, 16% responded they would be very or extremely likely, and 52% respondents would be somewhat likely or likely to accept intraoperative chemotherapy, even if it may not be necessary.
JOURNAL OF SURGICAL RESEARCH
(2023)
Review
Oncology
Ester Oneda, Alberto Zaniboni
Summary: Adjuvant chemotherapy with FP plus oxaliplatin has shown to reduce disease recurrence risk and mortality in resected MSI RCRC. The standard treatment is effective, but can be avoided in low-risk stage II patients. Immunotherapy is being considered as a potential alternative in the adjuvant setting.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
K. Yamazaki, T. Yamanaka, M. Shiozawa, D. Manaka, M. Kotaka, M. Gamoh, A. Shiomi, A. Makiyama, Y. Munemoto, T. Rikiyama, M. Fukunaga, T. Ueki, K. Shitara, H. Shinkai, N. Tanida, E. Oki, E. Sunami, A. Ohtsu, Y. Maehara, T. Yoshino
Summary: The study showed that a 3-month combination therapy had significantly less grade >= 2 PSN compared to the 6-month regimen. Shortening the therapy duration did not affect the 3-year DFS rate, indicating that a 3-month course of CAPDX can be an effective treatment option.
ANNALS OF ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Giovanni Centonze, Patrick Maisonneuve, Natalie Prinzi, Sara Pusceddu, Luca Albarello, Eleonora Pisa, Massimo Barberis, Alessandro Vanoli, Paola Spaggiari, Paola Bossi, Laura Cattaneo, Giovanna Sabella, Enrico Solcia, Stefano La Rosa, Federica Grillo, Giovanna Tagliabue, Aldo Scarpa, Mauro Papotti, Marco Volante, Alessandro Mangogna, Alessandro Del Gobbo, Stefano Ferrero, Luigi Rolli, Elisa Roca, Luisa Bercich, Mauro Benvenuti, Luca Messerini, Frediano Inzani, Giancarlo Pruneri, Adele Busico, Federica Perrone, Elena Tamborini, Alessio Pellegrinelli, Ketevani Kankava, Alfredo Berruti, Ugo Pastorino, Nicola Fazio, Fausto Sessa, Carlo Capella, Guido Rindi, Massimo Milione
Summary: This study analyzed a large series of neuroendocrine carcinomas (NECs) to validate previously identified prognostic factors and determine if additional parameters could be isolated. The most relevant predictors for prognosis were Ki-67 index, morphology, stage, and site. However, morphology was not a significant factor when Ki-67 was greater than or equal to 55%.
NEUROENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Halfdan Sorbye, Enrique Grande, Marianne Pavel, Margot Tesselaar, Nicola Fazio, Nicholas Simon Reed, Ulrich Knigge, Emanuel Christ, Valentina Ambrosini, Anne Couvelard, Eva Tiensuu Janson
Summary: This ENETS guidance paper provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma. It emphasizes the importance of surgical intervention for localized disease and recommends specific treatment options for metastatic disease. The paper also highlights the need for more prospective clinical trials to address the unmet needs in this field and improve the survival of patients with advanced disease.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Oncology
Dario Zerini, Marco Rotondi, Stefania Volpe, Eleonora Pisa, Emanuele Frigo, Cristiana Pedone, Michele Flospergher, Vincenzo Bagnardi, Samuele Frassoni, Cristiana Iuliana Fodor, Francesca Spada, Nicola Fazio, Daniela Alterio, Barbara Alicja Jereczek-Fossa
Summary: This retrospective analysis investigates the potential correlation between Ki-67 and radiotherapy response in neuroendocrine neoplasms. The results suggest that there is no significant association between Ki-67 and local tumor response to radiotherapy.
Article
Genetics & Heredity
Gaia Sambruni, Angeli D. Macandog, Jakob Wirbel, Danilo Cagnina, Carlotta Catozzi, Tiziano Dallavilla, Francesca Borgo, Nicola Fazio, Uberto Fumagalli-Romario, Wanda L. Petz, Teresa Manzo, Simona P. Ravenda, Georg Zeller, Luigi Nezi, Martin H. Schaefer
Summary: This study analyzes human RNA sequencing data and finds that the composition of bacteria associated with tumors is closely related to their clinical and molecular properties. Faecalibacterium prausnitzii, Coprococcus comes, Bacteroides spp., Fusobacterium spp., and Clostridium spp. are strongly associated with tumor properties. These results can improve patient stratification and provide insights for further research on the interaction between microbiota and tumors.
Article
Genetics & Heredity
Mariarosaria Calvello, Monica Marabelli, Sara Gandini, Elena Marino, Loris Bernard, Matteo Dal Molin, Giulia Di Cola, Cristina Zanzottera, Giovanni Corso, Nicola Fazio, Lorenzo Gervaso, Uberto Fumagalli Romario, Massimo Barberis, Aliana Guerrieri-Gonzaga, Lucio Bertario, Davide Serrano, Bernardo Bonanni
Summary: Gastric cancer has traditionally been overlooked in hereditary cancer research, but the advent of multigene panel testing has shed light on the involvement of additional genes, particularly those related to homologous recombination repair. Our study identified CDH1 and MSH2 as genes associated with early-onset diffuse and later-onset intestinal gastric cancers, respectively. Multigene panel testing was found to be advantageous in patients with unspecific phenotypes, although it posed challenges in result interpretation.
Article
Oncology
Davide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, Alessandra Di Liello, Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Maria Giulia Zampino, Nicola Fazio, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Summary: Rechallenge with EGFR inhibitors is a promising strategy in refractory RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients. The presence of plasma ctDNA RAS/BRAF mutations at pretreatment liquid biopsy analysis was not associated with the length of anti-EGFR drug-free interval. Liquid biopsy can be used to select suitable patients for EGFR inhibitor rechallenge.
Article
Oncology
Maurizio Muscaritoli, Alessandra Modena, Matteo Valerio, Paolo Marchetti, Roberto Magarotto, Silvia Quadrini, Filomena Narducci, Giuseppe Tonini, Teresa Grassani, Luigi Cavanna, Camilla Di Nunzio, Chiara Citterio, Marcella Occelli, Antonia Strippoli, Bruno Chiurazzi, Antonio Frassoldati, Giuseppe Altavilla, Antonio Lucenti, Fabrizio Nicolis, Stefania Gori
Summary: Malnutrition and cachexia in cancer patients have a negative impact on treatment, outcomes, quality of life, and survival. However, the risk of malnutrition and cachexia is still overlooked in cancer patients. A study revealed that 51% of patients already had nutritional deficiencies at their first oncology visit. These findings emphasize the importance of proactive, early management of malnutrition in cancer patients.
Article
Medicine, General & Internal
Carla Maria Irene Quarato, Beatrice Feragalli, Donato Lacedonia, Gaetano Rea, Giulia Scioscia, Evaristo Maiello, Concetta Di Micco, Cristina Borelli, Antonio Mirijello, Paolo Graziano, Lucia Dimitri, Rosanna Villani, Marco Sperandeo
Summary: This study aimed to examine the efficacy of pulmonary contrast-enhanced ultrasound (CEUS) in differentiating between malignant and benign peripheral lung lesions. The results showed that the dynamic parameters of CEUS cannot effectively differentiate between the two types of lesions.
Article
Medicine, General & Internal
Chiara A. Cella, Maren Knoedler, Marcia Hall, Michele Arcopinto, Vincenzo Bagnardi, Lorenzo Gervaso, Stefania Pellicori, Francesca Spada, Maria G. Zampino, Paola S. Ravenda, Samuele Frassoni, Antonio Passaro, Monica Milano, Alice Laffi, Nicola Fazio, Florian Lordick
Summary: The study validates the ONKOTEV score as a reliable risk assessment model for cancer-associated thrombosis, and suggests its adoption into clinical practice as a decision-making tool for primary prophylaxis.
Article
Oncology
Stefania Napolitano, Davide Ciardiello, Vincenzo De Falco, Giulia Martini, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Nicola Fazio, Massimo Di Maio, Sara Del Tufo, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troiani
Summary: The addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival in patients with refractory RAS wild-type metastatic colorectal cancer. Final overall survival results and posttreatment subgroup analysis support the role of anti-EGFR rechallenge in the continuum of care for these patients.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Endocrinology & Metabolism
Beata Kos-Kudla, Justo P. Castano, Timm Denecke, Enrique Grande, Andreas Kjaer, Anna Koumarianou, Louis de Mestier, Stefano Partelli, Aurel Perren, Stefan Staettner, Juan W. Valle, Nicola Fazio
Summary: This ENETS guidance paper provides up-to-date and practical advice on the management of well-differentiated nonfunctioning pancreatic neuroendocrine tumours (NF-Pan-NET). The authors discuss 10 troublesome questions in everyday clinical practice based on their extensive experience. Multidisciplinary decision-making is still necessary for the treatment of NF-Pan-NEN.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Oncology
Sun Young Rha, Do-Youn Oh, Patricio Yanez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel Gonzalez Fernandez, Jin Li, Maeve A. Lowery, Timucin Cil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S. Wyrwicz
Summary: This study compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy for locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. The results showed that participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity.
Article
Oncology
Lorenzo Gervaso, Luca Bottiglieri, Monica Isabel Meneses-Medina, Stefania Pellicori, Roberto Biffi, Uberto Fumagalli Romario, Stefano De Pascale, Isabella Sala, Vincenzo Bagnardi, Massimo Barberis, Chiara Alessandra Cella, Nicola Fazio
Summary: This study aimed to evaluate the impact of microsatellite instability (MSI) and HER2 status on clinical outcomes in patients with locally advanced gastric cancer (LAGC). The study found that patients with MSI-H had higher event-free survival (EFS) and overall survival (OS) compared to patients with MSI. However, further clinical trials and tumor molecular profiling are needed.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Letter
Medicine, General & Internal
Lorenzo Gervaso, Nicola Fazio
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
